The problem
Most drugs fail because the cells they were tested on never behaved like a human body: animal models mistranslate, and lab-grown human cells vary batch to batch. Researchers who need a defined, reproducible human cell — a neuron, a muscle fibre, a liver cell — either cannot get one or cannot trust the one they get, and regulators are steadily pushing the industry toward human-relevant New Approach Methodologies over animal testing.
How it works
bit.bio, founded in 2016 by Dr Mark Kotter from his Cambridge University labs after his discovery of the opti-ox technology, industrializes cell programming. An AI-enabled discovery platform finds the transcription-factor combinations that define each cell type, and patented opti-ox converts iPSCs into those types with unprecedented purity, consistency, and scale. The ioCells catalogue — 50+ products including wild-type, disease-model, and CRISPR-ready cells — gives drug developers off-the-shelf human biology. After a 2025 strategic reset that wound down internal therapeutics work and cut about a quarter of staff, the company is a pure platform-and-tools provider under CEO Przemek Obloj.
Pain points
Unpredictive animal models that kill candidates late; irreproducible lab-grown cells; scarce access to rare or diseased human cell types; and toxicology workflows still built around animal testing just as regulators demand alternatives.
Business model
Catalogue sales of ioCells products to research and pharma customers, global scale-up of manufacturing operations, expansion into the toxicology market, and generating cell datasets for AI model training.
Challenges
The 2025 pivot traded moonshot therapeutics upside for tools-business discipline — now bit.bio must prove catalogue revenue and toxicology adoption grow fast enough to justify the platform bet, while deep-pocketed reagents incumbents defend their accounts.
Funding
- Raised: $50M Series C led by M&G Investments (Jan 2026); earlier $103M Series B first close (Nov 2021, Arch Ventures, Tencent, others) and $41.5M Series A (Jul 2019).
- Valuation: no public priced valuation (MISSING).
Latest — January 2026
bit.bio closed a $50M Series C led by M&G Investments to accelerate product development, scale global operations and manufacturing, enter the toxicology market, and generate datasets for AI training — its first raise since the 2025 restructuring.